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Abstract 
Inositol Requiring Enzyme 1 alpha (IRE1α) is an ER-transmembrane endonuclease that is 
activated in response to ER stress as part of the unfolded protein response (UPR). Chronic 
activation of the UPR has been implicated in the pathogenesis of many common disease 
including diabetes, cancer and neurological pathologies such as Huntington’s and Alzheimer’s 
disease.  
7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde (4µ8C) is widely used as a specific 
inhibitor of IRE1α ribonuclease activity in mechanistic studies (IC50 of 6.89 µM in cultured 
cells). However, in this paper we showed that 4µ8C acts as a potent reactive oxygen species 
(ROS) scavenger both in a cell free assay and in cultured cells at concentrations lower than that 
widely used to inhibit IRE1α activity. We demonstrate that in vitro, 4µ8C effectively decreases 
xanthine/xanthine oxidase catalysed superoxide production with an IC50 of 0.2 µM. In cultured 
endothelial and clonal pancreatic beta-cells, 4µ8C inhibits angiotensin II-induced ROS 
production with IC50s of 1.92 and 0.29 µM respectively. In light of this discovery, conclusions 
reached using 4µ8C as an inhibitor of IRE1α should be carefully evaluated. However, this 
unexpected off-target effect of 4µ8C may prove therapeutically advantageous for the treatment 
of pathologies that are thought to be caused by, or exacerbated by, both oxidative and ER stress 
such as endothelial dysfunction and/or diabetes. 
 
Abbreviation list: 4µ8C (7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde), ROS 
(reactive oxygen species), AngII (angiotensin II), ER (endoplasmic reticulum), IRE1 (inositol 
requiring enzyme 1), UPR (unfolded protein response), IC (Inhibitory concentration), MIN6 
(Mouse insulinoma 6 cells), NOX (NADPH oxidases), AT1R (angiotensin type 1 receptor), 
XBP1 (X-box binding protein-1), PERK (PKR like ER Kinase), ATF6 (Activating 
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transcription factor 6), CM-H2DCFDA (5-(and-6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate),  bEnd.3 (Mouse microvascular cerebral endothelial 
cells). 
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Introduction  
The endoplasmic reticulum (ER) is the site for the synthesis and processing of secretory and 
membrane proteins. Perturbations in ER homeostasis that interfere with protein folding result 
in the activation of an adaptive response termed the Unfolded Protein Response (UPR) [1,2]. 
Chronic activation of the UPR has been implicated in many human pathologies including 
infectious, neurodegenerative, autoimmune, and metabolic conditions [3–5].  
The UPR is classically mediated by three ER-transmembrane proteins: PKR-like ER kinase 
(PERK), activating transcription factor 6 (ATF6), and inositol requiring enzyme 1α (IRE1α). 
IRE1α senses perturbations in ER homeostasis via its luminal domain which results in a 
conformational change [6,7]. This in turn promotes oligomerisation and the activation of its 
cytoplasmic protein kinase and RNAse domain. Activation of IRE1α leads to the cleavage and 
subsequent ligation of the mRNA encoding the X-box transcription factor-1 (XBP1) resulting 
in a frame shift and the synthesis of a truncated and transcriptionally active spliced form of 
XBP1 (XBP1s) [8]. In an attempt to relieve ER stress, XBP1s enhances the transcription of 
genes important in facilitating protein folding including the ER chaperone glucose regulated 
protein 78 [6,9]. However, chronic IRE1α activation can lead to programmed cell death through 
the activation of multiple signalling pathways (e.g.[6,10–12]). 
A number of small molecule inhibitors of IRE1α have been identified and characterised 
including 7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde (4µ8C) [13]. 4µ8C is an 
aromatic aldehyde that binds to IRE1α’s RNAse domain and inhibits its activity. This inhibitor 
has provided valuable insights into defining the mechanism of action of IRE1α in both cellular 
physiology and pathophysiology (e.g.[13–19]) . 4µ8C has also been used in animal studies [20] 
although its effectiveness in vivo is uncertain. A recent study investigating the effect of 4µ8C 
on insulin secretion has highlighted the potential of this inhibitor to have off-target effects [21]. 
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Consistent with this, in this report we demonstrate that 4µ8C not only inhibits IRE1α but also 
acts as a potent scavenger of ROS both in cell free assays and in cultured cells. In the light of 
this discovery conclusions reached using 4µ8C as a specific IRE1α RNAse inhibitor should be 
carefully considered.   
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Experimental  
Cell culture. Mouse Insulinoma 6 (MIN6) cells [22] were used between passages 25 and 35 at 
~80% confluence and cultured as previously described [23]. Mouse microvascular cerebral 
endothelial cells, bEnd.3 [24] were used between passage 24-34 (ATCC CRL-2299) and 
cultured in Dulbecco’s Modified Eagle Medium (Life Technology, Australia) supplemented 
with 10% fetal bovine serum (FBS; Bovogen Australia), at 37°C and 5% CO2.  
 
Quantification of superoxide in a cell-free enzyme system. The xanthine/xanthine oxidase cell-
free assay coupled with 5 μmol/L lucigenin-enhanced chemiluminescence [25] was used to 
assess the superoxide scavenging properties of 4µ8C. Briefly, to initiate the reaction, xanthine 
oxidase (50mU/ml) was added to Krebs-Hepes solution (NaCl 99 mmol/L, KCl 4.7 mmol/L, 
KH2PO4 10 mmol/L, MgSO4 1.2 mmol/L, NaHCO3 25 mmol/L, glucose 11 mmol/L, CaCl2 
2.5 mmol/L, and EDTA 0.026 mmol/L, pH 7.4) containing xanthine (100 μmol/L) and 
lucigenin (5μmol/L). Where indicated experiments were performed in the absence or presence 
of superoxide dismutase (SOD; 250U/ml), 4µ8C (3nM - 30µM), DMSO ((0.1%) vehicle for 
4µ8C), or Tiron (0.3 – 3000µM). Superoxide counts were measured using a BMG Clariostar 
plate reader (BMG Labtech, Melbourne, Australia). Background counts were then subtracted, 
and the superoxide level was expressed as relative luminescence units (RLU). 
 
Quantification of cellular superoxide levels. Superoxide levels were measured using L-012 
(100 µmol/l) enhanced chemiluminescence as previously described [26]. Cells were plated on 
a 96-well Optiplate (PerkinElmer, Melbourne, Australia). Upon treatments, 20 µL of 1mol/l L-
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012 (in Krebs-Hepes) was added per well in semi-darkness to give a final concentration of 100 
µmol/l. After treatments superoxide counts were measured using a BMG Clariostar plate reader 
over 90 min (BMG Labtech, Melbourne, Australia; 45 cycles, 3 s per well). The accumulated 
luminescence counts obtained were subtracted from the corresponding vehicle control and 
expressed as RLU.  
 
Measurement of intracellular ROS generation. Intracellular ROS generation was measured 
using the cell-permeable ROS detector 5-(and-6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA) (Thermo Scientific Australia). Briefly, 
cells incubated in phenol-red free growth media were loaded with CM-H2DCFDA (10 
μmol/L). The oxidation of CM-H2DCFDA was captured kinetically (Ex/Em: 485/528 nm) at 
37°C for 90 min. ROS production is expressed as accumulated relative fluorescence units 
(RFU).  
 
Statistical analysis Data are expressed as mean +/- SEM, unless otherwise stated. Data were 
analysed by one-way ANOVA followed by Tukey’s post-hoc test for multiple comparison 
between means using Prism 6 (GraphPad Software, USA). Differences were considered 
statistically significant at p < 0.05. 
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Results 
4µ8C is a potent superoxide scavenger in a cell free assay. While studying the role of 
angiotensin II (AngII), an inducer of ROS, in the development of beta cell dysfunction [26] we 
observed that the commonly used IRE1α inhibitor 7-hydroxy-4-methyl-2-oxo-2H-chromene-
8-carbaldehyde (4µ8C) inhibited, not only the activation of IRE1α, but also PERK, indicating 
that 4µ8C may have off-target effects (unpublished observations). Many naturally occurring 
antioxidants are polyphenolic compounds that act as free radical scavengers [27]. As 4µ8C 
[13] (Figure 1a) is a polyphenolic compound it also has the potential to act as a free radical 
scavenger. To investigate this possibility, cell-free xanthine/xanthine oxidase assays were 
performed using the chemiluminescent probe lucigenin. As expected the addition of xanthine 
oxidase to a solution containing xanthine and lucigenin led to a rapid increase in superoxide 
levels (figure 1b), which was abolished in the presence of SOD. Thus confirming that the 
reaction between xanthine and xanthine oxidase generates superoxide [25]. Furthermore, the 
addition of 4µ8C alone (i.e. in the absence of xanthine oxidase) had no effect on relative 
luminescence (figure 1b). Next, we measured superoxide levels, in the presence or absence of 
either increasing concentrations of the IRE1α inhibitor 4µ8C or as a positive control, tiron, a 
classical ROS scavenger [28]. 4µ8C (3mM to 30µM) (Figure 1c) or tiron (0.3µM to 3mM) 
(Figure 1d) reduced superoxide levels generated by the xanthine/xanthine oxidase cell-free 
assay in a concentration-dependent manner. Tiron inhibited xanthine/xanthine oxidase 
superoxide production with an IC50 of 7.3x10-6M, whereas 4µ8C inhibited superoxide 
production with an IC50 of 2.0x10-7M (figure 1e). Therefore, 4µ8C is a more potent superoxide 
scavenger than tiron in this cell-free enzyme assay. 
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4µ8C inhibits angiotensin II-induced superoxide production in pancreatic beta-cells and 
brain endothelial cells. Angiotensin II (AngII) increases cellular superoxide production by 
activating the NADPH oxidases (NOX) via the angiotensin type 1 receptor (AT1R) [29]. 
Therefore, to determine whether 4µ8C also acts as an antioxidant in cells, the mouse pancreatic 
beta-cell line, MIN6, and the mouse cerebral endothelial cell line, bEnd3, were treated with 
AngII in the presence or absence of 4µ8C (30µM) or, as control, the AT1R antagonist 
irbesartan (IRB). Superoxide levels were then measured using the luminol-based 
chemiluminescent probe, L-012. As anticipated, AngII caused a significant increase in 
superoxide production in both MIN6 (Figure 2a) and bEnd3 cells (Figure 2b) relative to control 
and this was blocked by IRB (Figure 2a and b). Importantly, AngII-induced increase in 
superoxide, in both cell lines was effectively inhibited by 30µM 4µ8C (Figure 2a and b); a 
concentration that is commonly used to inhibit IRE1α’s RNAse activity. 
To formally demonstrate that AngII-generated superoxide production was through the 
activation of NOX rather than ER stress-induced IRE1α activation, MIN6 and bEnd.3 cells 
were treated with AngII in the presence or absence of two NOX inhibitors, 
diphenyleneiodonium (DPI) and apocynin [30](Figure 2c and d). AngII treatment caused an 
increase in superoxide production which was effectively inhibited by both of the NOX 
inhibitors. This provides evidence that AngII-induced superoxide was generated through the 
activation of NOX and not IRE1α activation.  
4µ8C concentration-dependent inhibition of angiotensin II-induced superoxide production 
in MIN6 cells and bEnd.3 cells. To investigate the potency of 4µ8C at inhibiting AngII-
induced ROS production in cells, MIN6 and bEnd.3 cells were treated with AngII in the 
presence of increasing concentrations of 4µ8C and superoxide production was measured using 
L-012 (Figure 3). The addition of 4µ8C led to the concentration-dependent inhibition of AngII-
generated superoxide with an IC50 of approximately 1.92µM in MIN6 cells, (Figure 3a) and 
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0.293µM in bEnd.3 cells (Figure3b). As 4µ8C inhibits IRE1α in mammalian cultured cells 
with an IC50 of 6.89µM [13], 4µ8C antioxidant activity is more potent than it ability to inhibit 
IRE1α RNAse activity.  
 
4µ8C inhibits AngII-induced ROS production in MIN6 and bEnd.3 cells. As further evidence 
that 4µ8C is an antioxidant in mammalian cells, MIN6 and bEnd.3 cells were treated with 
AngII in the presence and absence of 4µ8C and changes in intracellular ROS was detected 
using 2’,7’ –dichlorofluorescin diacetate (CM-H2DCFDA),  a fluorogenic dye that reacts with 
hydroxyl, hydrogen peroxide, peroxynitrite, and to a lesser extent superoxide [31]. Because 
hydrogen peroxide is a downstream product of superoxide, CM-H2DCFDA fluorescence is 
often used to implicate superoxide production [31]. Using CM-H2DCFDA, we confirmed that 
AngII increases ROS production in both MIN6 cells (Figure 4a) and bEnd.3 cells (Figure 4b), 
and that this is inhibited by apocynin. Importantly, AngII stimulates ROS production was also 
inhibited by 4µ8C (30µM). Thus 4µ8C acts as a ROS scavenger in cultured mammalian cells.  
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Discussion 
Cell-permeable low-molecular weight inhibitors are used extensively to understand the role of 
specific enzymes in cellular physiology. Unfortunately, these compounds often lack specificity 
and display multiple off target effects that can lead to the misinterpretation of data. Our data 
demonstrates that 4µ8C, at concentrations widely used to inhibit IRE1α activity, also acts as a 
potent ROS scavenger both in a cell free assay and in cultured cells. Importantly, no other 
studies have shown that 4µ8C acts as a ROS scavenger.  
The IC50 values for scavenging ROS by 4u8C differed in the two cell types used in this study. 
Although this may reflect the relative ability of AngII to stimulate ROS in these cells, 
comparison of ROS production between different cell types is difficult due to differences in, 
for example, ROS detector probe loading into the cell. Regardless, the effectiveness of the 
IRE1α inhibitor as a ROS scavenger is likely to be dependent on the amount of ROS being 
generated. In cells, such as phagocytes, that generate high concentration of ROS, the IC50 of 
the inhibitor against IRE1α RNAse activity may be greater than its IC50 for scavenging ROS. 
Interestingly, 4u8C has been used in macrophages to provide evidence for the role of IRE1α in 
ROS-dependent killing of bacteria [32]. Whether some or all of the effects of 4u8C reported 
on ROS-dependent killing were mediated by the antioxidant properties of 4u8C, as 
demonstrated in the report, is unclear but again highlights the importance of this study. 
Recently, Sato et al examined the role of IRE1α on insulin secretion in pancreatic β-cells using 
4u8C. They discovered that 4u8C inhibited insulin secretion even in cells lacking the IRE1α 
RNAse domain demonstrating that 4u8C is able to block insulin secretion independent of the 
IRE1α/XBP1 pathway [21]. Given the results presented in this report, it is possible that the 
inhibitory effects of 4u8C on insulin secretion are through the scavenging of ROS. 
12 
 
4µ8C ability to act as a potent ROS scavenger is likely due to its coumarin type conjugated 
structure (Figure 1a), which can enable stabilisation of the free radical either by donation of a 
hydrogen atom or an electron [33]. This stabilisation is a result of the numerous resonance 
forms that are possible once the 4µ8C radical is formed, i.e. the 4u8c radical is resonance 
delocalised. 
This off-target effect is a particular problem for researchers interested in delineating the role of 
IRE1 in ER stress responses, as oxidative stress can induce ER stress and conversely ER stress 
can promote oxidative stress [1,34]. Despite the potential problems of interpreting data using 
4µ8C, off-target effects of low molecular cell permeable inhibitors can be advantageous in a 
clinical setting. For example, Gleevec (Imatinib), initially developed as an inhibitor of BCR-
Abl, was later found to also inhibits the c-kit and platelet-derived growth factor receptor-A. 
This off target effect proved advantageous in its use as a treatment of gastrointestinal stromal 
tumour (GIST) [35]. Given that we demonstrate that 4µ8C can also act as a potent antioxidant 
this may prove therapeutically advantageous for the treatment of pathologies that are thought 
to be caused by, or exacerbated by, both oxidative and ER stress e.g. endothelial dysfunction 
or diabetes [1,4,36–38]. Therefore it is possible that 4µ8C, or a more pharmokinetically 
favourable structural analogue, may prove to have therapeutic value against such diseases. 
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Figure legends 
Figure 1. The superoxide scavenging effects of 4µ8C. (a) The chemical structure of 4µ8C. 
(b) The effect of addition of xanthine oxidase (XO) to xanthine (XA) on superoxide levels in 
the presence and absence of superoxide dismutase (SOD; 250U) and the effect of 4µ8C (30µM) 
alone on luminescence. (c and d) Superoxide was generated from the xanthine/xanthine oxidase 
reaction in the presence or absence of (c) 4µ8C (3nM – 30µM) or Vehicle (DMSO), (d) Tiron 
(0.3µM – 3000µM) or vehicle (saline) (e) Concentration-inhibition curves for 4µ8C (solid 
circles) and Tiron (solid squares) respectively.  In all cases, superoxide was detected using 
lucigenin-enhanced chemiluminescence. All results are expressed as the mean +/- S.E.M of at 
least five independent experiments. 
 
Figure 2. Angiotensin II induced superoxide formation in cells is blocked by 4µ8C. (a) 
MIN6 cells or (b) bEnd.3 cells were treated with 100 nM AngII in the absence or presence of 
30 µM 4u8C or IRB (100 nM). (c) MIN6 cells or (d) bEnd.3 cells were treated with 100 nM 
AngII in the absence or presence of diphenyleneiodonium (DPI; 10 µM) or apocynin (10 µM). 
In all cases the formation of superoxide was detected using L-012. The results are presented as 
the mean RLU + S.E.M of at least five independent experiments ** p<0.01 versus control, †† 
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p<0.01 for the compared groups. 
 
Figure 3. Dose-dependent effects of 4µ8C on superoxide formation. (a) MIN6 and (b) 
bEnd.3 cells were stimulated with 100 nM AngII in the absence or presence of increasing 
concentration of 4u8C (3 nM-30 µM) and the results plotted as concentration-inhibition curves. 
The formation of superoxide was detected using L-O12 and the results presented as the mean 
+/- S.E.M of six independent experiments.  
 
Figure 4. The intracellular free radicals scavenging effect of 4µ8C. (a) MIN6 and (b) 
bEnd.3 cells were stimulated with 100 nM AngII in the absence or presence of 30µM 4u8C or 
10µM apocynin. The formation of intracellular free radicals was detected using CM-
H2DCFDA. The results are presented as the mean + S.E.M of three independent experiments. 
** p<0.01 vs control; †† p<0.01 for the compared groups. 
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